Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer

Objective Our study aimed to evaluate the association between timing of cytoreductive surgery and pattern of presentation of the first recurrence in patients with advanced ovarian cancer. We also aimed to assess the impact of the pattern of recurrence on post-relapse overall survival according to surgical timing. Methods This retrospective multicenter study evaluated patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV ovarian cancer. Patients had undergone either primary debulking surgery, early interval debulking surgery after 3–4 cycles of neoadjuvant chemotherapy, or delayed debulking surgery after 6 cycles, with minimal or no residual disease, between January 2008 and December 2015. Survival analyses were conducted using the Log-rank test and the Cox model. Cumulative incidences of the different patterns of recurrence were estimated using a competing risks methodology. Results A total of 549 patients were included: 175 (31.9%) patients had primary, 224 (40.8%) early interval, and 150 (27.3%) delayed debulking surgery. The cumulative incidence of peritoneal recurrences at 2 years was higher with increasing neoadjuvant cycles (24.4%, 30.9% and 39.2%; p=0.019). For pleural or pulmonary recurrences, it was higher after early interval surgery (9.9%, 13.0% and 4.1%; p=0.022). Median post-relapse overall survival was 33.5 months (95% confidence interval (CI) (24.3 to 44.2)), 26.8 months (95% CI (22.8 to 32.6)), and 24.5 months (95% CI (18.6 to 29.4)) for primary, early interval, and delayed debulking surgery groups, respectively (p=0.025). The pattern of recurrence in a lymph node (hazard ratio (HR) 0.42, 95% CI (0.27 to 0.64)), delayed surgery (HR 1.53, 95% CI (1.11 to 2.13)) and time to first recurrence (HR 0.95, 95% CI (0.93 to 0.96)) were associated with post-relapse overall survival. For primary and early interval surgery, lymph node recurrences were associated with significantly longer post-relapse overall survival. Conclusions The pattern of first recurrence was associated with timing of surgery, with peritoneal recurrences being more frequent with the increasing number of cycles of neoadjuvant chemotherapy. Lymph node recurrences were associated with better prognosis, having higher post-relapse overall survival. This improved prognosis of lymphatic recurrences was not observed in patients who underwent delayed surgery.

[1]  F. Guyon,et al.  The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer. , 2022, Gynecologic oncology.

[2]  G. Ferron,et al.  Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer , 2021, Archives of Gynecology and Obstetrics.

[3]  G. Scambia,et al.  Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) , 2020, International Journal of Gynecological Cancer.

[4]  E. Darai,et al.  Isolated lymph node recurrence in epithelial ovarian cancer: Recurrence with better prognosis? , 2020, European journal of obstetrics, gynecology, and reproductive biology.

[5]  O. Elyashiv,et al.  Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome. , 2020, Gynecologic oncology.

[6]  E. Sala,et al.  Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? , 2019, Gynecologic oncology.

[7]  L. Chiva,et al.  What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer? , 2016, Annals of Surgical Oncology.

[8]  A. Gadducci,et al.  Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study , 2016, International Journal of Gynecologic Cancer.

[9]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[10]  G. Scambia,et al.  Timing and Pattern of Recurrence in Ovarian Cancer Patients with High Tumor Dissemination Treated with Primary Debulking Surgery Versus Neoadjuvant Chemotherapy , 2013, Annals of Surgical Oncology.

[11]  A. Gadducci,et al.  Prognostic Factors and Clinical Outcome of Patients With Recurrent Early-Stage Epithelial Ovarian Cancer: An Italian Multicenter Retrospective Study , 2013, International Journal of Gynecologic Cancer.

[12]  S. Grénman,et al.  Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? , 2013, Gynecologic oncology.

[13]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[14]  D. Chi,et al.  Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. , 2006, Gynecologic oncology.

[15]  G. Scambia,et al.  Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. , 2006, European journal of cancer.

[16]  E. Cotte,et al.  Quantitative prognostic indices in peritoneal carcinomatosis. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  Y. Taketani,et al.  Patients with ovarian carcinoma upstaged to Stage III after systematic lymphadenctomy have similar survival to Stage I/II patients and superior survival to other Stage III patients , 1998, Cancer.

[18]  P. Sugarbaker Peritonectomy Procedures , 1995, Surgical oncology clinics of North America.

[19]  S. Rubin,et al.  Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.